

Special Issue

Vaccines and Prevention of Infections in Early Life

Message from the Guest Editor

The focus on the well-being of our population begins in the neonatal period and early infancy. Early-life infections have high mortality and morbidity and may have a tremendous negative impact on our health rates. Significant progress has been made towards the prevention of infections in early life. However, there are still many challenges to overcome. Infections from pathogens continue to pose a significant burden for neonates and young infants. Extensive research focuses on the development of novel maternal vaccines and ways to boost maternal immunity and placental antibody transfer to protect the offspring. Apart from maternal vaccines, there are also other preventive measures under investigation that may be employed. There are still unanswered questions on the acceptance and implementation of the existing maternal vaccines, as well as their impact on the infant's immunity and immune responses to other vaccines. Further research on the epidemiology of early-life infections, screening strategies and preventive measures that will advance our understanding and reduce the instances of disease in this population is of great importance.

Guest Editor

Dr. Eleni Vergadi

Department of Mother and Child, School of Medicine, University of Crete, 71003 Heraklion, Greece

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/146351

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).